Researchers at Vanderbilt Publish First Study from PHA’s 2018 Research Room

2018-11-29T21:44:15+00:00 November 29th, 2018|

Using fitness devices and cell phones, pulmonary hypertension (PH) researchers compared the physical activity of individuals with and without pulmonary arterial hypertension (PAH) in the first research study published using data collected through the Research Room at the Pulmonary Hypertension Association’s (PHA’s) 2018 International PH Conference and Scientific Sessions in Orlando, Fla. By collecting

Common Antacids: Beneficial for Patients with Pulmonary Hypertension?

2018-11-16T23:15:42+00:00 November 16th, 2018|

by Phyllis Hanlon, Contributing Writer Certain over-the-counter (OTC) medications such as Pepcid®, Tagamet® and Zantac® are used to treat ulcers and excess stomach acid. These drugs, technically known as histamine-2 (H2) receptor antagonists, suppress stomach acid, which can be caused by certain foods, caffeine, allergens, insulin and other substances. A recent analysis shows these common

PAH Study: Is Morbidity Related to Mortality?

2018-11-09T22:34:24+00:00 November 9th, 2018|

by Phyllis Hanlon, Contributing Writer People with a serious illness such as pulmonary hypertension (PH) must form a partnership with their health care providers to effectively manage the disease in a way that enhances quality of life. Two recent clinical trials related to World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or

PH with COPD: Is Sildenafil an Effective Treatment Option?

2018-10-26T20:46:19+00:00 October 26th, 2018|

by Phyllis Hanlon, Contributing Writer All of the 14 targeted therapies for pulmonary hypertension (PH) are approved for use in patients with World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or PAH), with one therapy also approved for use in patients with inoperable or recurrent WHO Group 4 PH (chronic thromboembolic pulmonary hypertension,

Using a Risk Score Calculator to Predict Survival Rates

2018-10-12T21:31:14+00:00 October 12th, 2018|

by Phyllis Hanlon, Contributing Writer The Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL registry) is a study of approximately 3,500 people with World Health Organization (WHO) Group 1 pulmonary hypertension (pulmonary arterial hypertension, or PAH) in the U.S. Study participants who were followed 2006-2011 contributed important information to the pulmonary hypertension (PH)

The DIBOSA Study: The 6MWT Helps Predict PH in Patients with SSc

2018-10-05T20:46:46+00:00 October 5th, 2018|

by Phyllis Hanlon, Contributing Writer Research has found that World Health Organization (WHO) Group 1 pulmonary hypertension (PH) (pulmonary arterial hypertension, or PAH) affects 8 to 12 percent of patients who have systemic sclerosis (SSc, a form of scleroderma – a disease that causes hardening and tightening of the skin and connective tissues) and

Results of Portopulmonary Hypertension Trial Released at European Respiratory Society Meeting

2018-09-28T16:35:32+00:00 September 28th, 2018|

Actelion Pharmaceuticals Ltd. has announced the results of the first randomized controlled trial in portopulmonary hypertension (PoPH), which showed that macitentan (Opsumit®) significantly improved pulmonary vascular resistance (PVR) compared with a placebo. Macitentan is currently approved for the treatment of pulmonary arterial hypertension (PAH). Presented as a late-breaking oral presentation at the European Respiratory

Analyzing the Effects of PH in Patients with Kidney Disease

2018-09-21T20:51:33+00:00 September 21st, 2018|

by Phyllis Hanlon, Contributing Writer According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) approximately 14 percent of the general population has chronic kidney disease (CKD); more than 661,000 Americans have kidney failure and 468,000 of these are on dialysis. Furthermore, CKD often occurs along with other medical conditions, earning the

Treating PH: Joint Symposium Discusses Options

2018-09-07T20:04:55+00:00 September 7th, 2018|

by Phyllis Hanlon, Contributing Writer Although there are 14 different Food and Drug Administration (FDA)-approved therapies for treating World Health Organization (WHO) Group 1 pulmonary hypertension (PH) (pulmonary arterial hypertension, or PAH), there remains a need for treatments that can be used across varying classifications of PH. In 2017, the Critical Care Medicine Department of

Examination of PHAR Data Shows Few Patients are Referred to Palliative Care

2018-08-31T15:42:34+00:00 August 31st, 2018|

Although treatment options for WHO Group 1 PH (pulmonary arterial hypertension, or PAH) have increased over the past few decades, symptom severity and quality of life still impose significant burden on patients. Palliative care – often confused with hospice care – is goal-oriented care for patients with chronic illnesses that help to balance life-saving